

# Business Activities

The Fujifilm Group develops businesses in three business fields: Imaging Solutions, Healthcare & Material Solutions, and Document Solutions. This section shows the state of business activities for each field.

## FY2018/3 Fujifilm Group Topics

Here is information on key topics for the Fujifilm Group in FY2018/3.

### Bio CDMO\* business

#### Expansion of Biopharmaceuticals Production Capacity with New Facility Operating at U.S. Site

At FUJIFILM Diosynth Biotechnologies Texas, LLC (Texas, U.S.), newly completed facilities compliant with the latest manufacturing control and quality control regulations came into operation in January 2018. As biopharmaceuticals are gaining an increasing share of the overall pharmaceuticals market due to the potential to achieve strong results with very few side effects. In addition to making further progress through the growth strategies of this business domain, Fujifilm will also contribute to the further development of the pharmaceuticals industry through the stable provision of high-quality pharmaceuticals.

\* CDMO stands for Contract Development & Manufacturing Organization. CDMO provide clients such as pharmaceutical and biotechnology companies with a wide range of services from cell line development in the early stage of pharmaceutical development to process development, stability testing, manufacturing of investigational drugs, and commercial drug manufacturing.



The new production facility which started operation

### Graphic/Document business

#### Integration of Sales Functions for Inkjet Digital Presses for the Printing Market

In October 2017, the domestic sales functions for inkjet digital presses of FUJIFILM Corporation and Fuji Xerox Co., Ltd. for the printing market were integrated into FUJIFILM Digital Press Co., Ltd., one of FUJIFILM Corporation's sales companies. We will deliver optimal products and solutions in the printing market where digitization is advancing through the establishment of a sales framework with strong proposal and sales capabilities, providing the entire range of both companies' extensive product lineups.



Inkjet digital press  
Jet Press 750S

### Pharmaceutical business

#### Construction of a New Plant at FUJIFILM Toyama Chemical Co., Ltd.'s Pharmaceutical Manufacturing Site

Fujifilm will invest approximately JPY 4 billion to build a new manufacturing facility equipped with advanced production systems utilizing cutting-edge ICT technologies and more at the pharmaceutical production site of FUJIFILM Toyama Chemical Co., Ltd. The new facility will manufacture liposome drugs utilizing proprietary technologies such as anti-cancer agent *FF-10832* for use in clinical studies and commercial marketing, ensuring the stable supply of high-quality liposome formulas. Construction of the new facility is scheduled to begin their operations in February 2020. On October 1, 2018, Toyama Chemical Co., Ltd., which conducts the research, development, manufacture and sales of small-molecule pharmaceutical products, and FUJIFILM RI Pharma Co., Ltd., which researches, develops, manufactures, and markets radiopharmaceuticals, merged to form FUJIFILM Toyama Chemical Co., Ltd., in order to accelerate the development of new diagnostic and therapeutic drugs.



Exterior of the new facility (illustration)

### Regenerative medicine business

#### Acquisition of Leading Cell Culture Media Companies

In June 2018, Fujifilm concluded an agreement to acquire all of the outstanding shares in Irvine Scientific Sales Company, Inc. (California, U.S.) and IS JAPAN CO., LTD., leading companies in cell culture media, for about US\$800 million.

The market for cell culture media is expanding following the dramatic growth in demand for biopharmaceuticals centered around antibody drugs and the increasing need for treatments using cells, and its annual growth is expected to be approximately 10% going forward.

By acquiring these companies, we aim to accelerate growth of cell culture media business and maximize Group synergies in the bio CDMO, regenerative medicine and reagent businesses, thereby speeding up healthcare business growth.

#### What's "culture media"?

It contains the nutrients required for the growth and proliferation of cells—and which are essential for cell culturing in the R&D and manufacture of biopharmaceuticals and regenerative medicine products.



# Imaging Solutions


## Photo Imaging

Provides photo-related products and services, ranging from photo-taking to printing


## Optical Device and Electronic Imaging

Provides products such as digital cameras, interchangeable lenses, and TV lenses


### Proportion of revenue



### Revenue



### Operating income/ Operating margin



### Business opportunities

- Growth in the number of photos taken and printing needs due to smartphone proliferation
- Expansion of demand in emerging countries for instant photo systems
- Acceleration of single lens reflex camera users switching to mirrorless cameras
- Growth in demand for lenses as IoT advances and security becomes more important
- Increase in demand for high-performance lenses from shifts to 4K and 8K imaging

### Risks

- Escalation of competition in the high-end mirrorless camera market
- Enhancement of smartphone camera performance (driving users away from cameras)
- Escalation of competition in the high-performance industrial lens market due to competitors' technological enhancements

### Performance Summary of FY2018/3

The consolidated revenue amounted to JPY 383.0 billion (up 12.1% from the previous fiscal year), due to a significant increase in sales in the electronic imaging business.

Consolidated operating income amounted to JPY 56.0 billion (up 52.0% from the previous fiscal year), due to the improvement in profitability in each business and other factors.

In the photo imaging business, sales rose led by instant photo systems such as *instax* instant cameras and *instax* films. Additionally, brisk value-added printing business contributed to sales expansion.

In the optical device and electronic imaging business, sales increased in the electronic imaging field on the back of strong sales of mirrorless digital cameras such as *FUJIFILM X-H1*. Sales also grew in the optical device field, reflecting brisk sales of the *MK Series* of cinema lenses and various industrial lenses including those for automobiles and projectors.

## Photo Imaging

Revenue JPY **255.4** billion

### Principal Products and Services

#### ▶ Instant photo systems

#### ▶ Printing materials

Photographic paper and chemicals for color prints  
Inkjet paper and ink  
Thermal paper and ribbon

#### ▶ Printer devices

Minilabs (silver type, inkjet type)  
Thermal photo printers

#### ▶ Labs and photo printing services

Value-added printing business such as *Photobook*  
Photo printing services

#### ▶ Photographing sensitive materials

Color negative films  
Reversal films  
*QuickSnap*



instax SQUARE SQ6

### Performance Highlights and Major Initiatives

- Sales of instant photo systems centered on the *instax* series and *instax* films that enable users to enjoy on-the-spot printing of photos were strong.
- Sales of the hybrid instant camera *instax SQUARE SQ10*, the smartphone printer *instax SHARE SP-3*, and square format film were strong.
- Generated new demand for printing photos by offering *Super Easy Print Applications*, a smartphone app for ordering prints of smartphone photos.
- Sales of value-added printing services continued to grow and contribute to sales, including *Wall Decor* printing services that enable users to enjoy decorating their walls, *Photobook* services including *Year Album* which select and layout photos automatically, and *PhotoZINE*, a photobook that can be finished immediately in stores.

## Optical Device and Electronic Imaging

Revenue JPY **127.6** billion

### Principal Products and Services

#### ▶ X Series digital cameras

#### ▶ GFX Series medium-format mirrorless digital camera with a large-sized sensor

#### ▶ Interchangeable lenses for digital cameras

#### ▶ TV lenses, cinema lenses

#### ▶ Security lenses

#### ▶ Automotive lenses

#### ▶ Projector lenses



FUJINON UA107x8.4



FUJIFILM X-H1



FUJIFILM GFX 50S

### Performance Highlights and Major Initiatives

#### Electronic imaging

- Sales were brisk for the X Series of digital cameras, especially the flagship *FUJIFILM X-H1* model and the *FUJIFILM X-A5* model with a compact, lightweight body.
- Sales were strong for the *FUJIFILM GFX 50S*, a medium-format mirrorless digital camera with a large-sized sensor, and various interchangeable lenses.



#### Optical device

- Sales were solid for various industrial-use lenses including those for automobiles and projectors, and the *MK Series* of cinema camera lenses.
- Launched the *UA24x7.8BE*, a compact, lightweight 4K high-definition compatible broadcast lens with a high zoom ratio of 24x.

## Business topics

### Imaging

## Expansion of Instant Photo Business



In May 2017, we launched the hybrid instant camera *instax SQUARE SQ10*. This product is the first in the *instax* series to be equipped with digital features, enabling images to be edited and processed before printing. It uses the square format, which is popular on SNS and other platforms. Aside from the *instax SQUARE SQ10*, our lineup of products that have adopted the square format includes the instant camera *instax SQUARE SQ6* and the smartphone printer *instax SHARE SP-3*.

The sales of instant photo systems are growing in the United States and Europe and the products are extending their reach in emerging countries, with many people around the world, especially younger people, using them.

By suggesting new ways to use the *instax* instant photo systems and broadening its horizons, we are generating stable earnings along with adding richness to people's lives with photos by delivering the fundamental photographic values of "shooting, preserving, displaying, and sharing" photos.



# Healthcare & Material Solutions

## Healthcare

Develops businesses in the fields of medical systems, pharmaceuticals, bio CDMO, regenerative medicine, and life sciences; operates business in the three health fields of prevention, diagnosis, and treatment

## Highly Functional Materials

Develops the industrial product business which includes display materials, non-destructive testing equipment, and various types of highly functional films; the electronic materials business which includes semiconductor processing materials; and the fine chemicals business which provides highly functional compounds and reagents


## Recording Media

Provides products including computer tape and data archive services


## Graphic Systems

Provides inkjet digital presses, industrial inkjet printheads, graphic arts films and computer-to-plate (CTP) plates


### Proportion of revenue



### Revenue



### Operating income/ Operating margin



## Healthcare

### Business opportunities

- Increasing needs for solutions that support medicine and improve work efficiency due to an aging population and shortages of medical practitioners
- Increasing unmet medical needs, mainly for cancer, rare diseases and gene therapies
- Expanding market of the biopharmaceuticals, which is expected to deliver high efficacy with few side effects
- Spread of regenerative medicine through provision of regenerative medical products
- Rising awareness of health, including living healthy lives and lifestyle-related ailments

### Risks

- Fiercer competition from the rise of new entrants
- Strengthened regulatory response for medical equipment
- Increasing difficulty of new drug discovery
- Heightened competition from technological innovations in the biopharmaceuticals market

## Highly Functional Materials, Recording Media, Graphic Systems

### Business opportunities

- Stronger demand for display-related materials from growth in the OLED and touch panel market
- Expansion in the semiconductor market from growth in smartphones and data centers
- Growing needs for efficiently storing enormous volumes of data at low cost in the era of big data
- Expansion in the industrial printing market, such as textiles and packaging, and growth in inkjet digital printing in these markets

### Risks

- Tougher competition from alternative materials for TAC film
- A more competitive environment in the semiconductor materials market
- Weaker than expected demand in the graphic arts film and printing plate markets
- Higher raw materials prices

## Performance Summary of FY2018/3

Revenue amounted to JPY 1,002.6 billion (up 11.5% from the previous year) due to strong sales in the medical systems business, electronic materials business and others.

Operating income amounted to JPY 92.8 billion (up 11.8% from the previous fiscal year) due to improvement of profitability in each business.

In the medical systems business, revenues increased due to strong sales in all business fields such as X-ray imaging diagnostics, medical IT, endoscopes, ultrasound, and in-vitro diagnostic (IVD). In the pharmaceuticals business, revenues decreased due to an adverse impact from generic drugs in the small-molecule drug field. In the bio CDMO business, however, contract work was firm for process development and the manufacturing of pharmaceuticals. In the regenerative medicine business, order receipts were favorable for autologous cultured epidermis *JACE* made by Japan Tissue Engineering Co., Ltd. (J-TEC), contributing to revenues. Revenues also increased in the life science business.

In the display materials business, sales increased for touch panels, OLED-related materials and other products in new fields. In the industrial materials business, sales remained strong for *EXCLEAR* touch panel sensor film. In the electronic materials business, sales grew sharply for advanced products such as photoresist and photolithography materials. In the fine chemicals business, sales expanded for highly functional compounds such as polymerization initiators, a raw material in superabsorbent polymers used in disposable diapers and other consumer staples.

In the recording media business, sales decreased due to the inventory adjustment of magnetic tape for data storage and other factors.

In the graphic systems business, sales declined owing to weaker overall demand for graphic arts film and printing plates. In the inkjet business, sales were favorable for ink and industrial inkjet printheads.

## Healthcare

Revenue JPY **443.0** billion

### Medical Systems

#### Principal Products and Services

- ▶ Digital X-ray imaging diagnostic systems: *FCR, DR*
- ▶ Medical-use picture archiving and communications systems *SYNAPSE*
- ▶ Endoscope systems
- ▶ Ultrasound diagnostic equipment
- ▶ In-vitro diagnostic (IVD) systems
- ▶ X-ray films



Medical-use picture archiving and communications systems *SYNAPSE*

#### Performance Highlights and Major Initiatives

- Sales increased due to strong sales in all fields.
- Sales of *FUJIFILM DR CALNEO AQRO*, an ultra-light weight mobile digital X-ray system with its weight cut down by 1/5 compared to the previous model, were strong.
- *FUJIFILM DR CALNEO Go PLUS*, a prop move typed mobile digital X-ray car, which has prominent forward visibility and has been well evaluated in medical treatment sites.
- Sales of systems, particularly *SYNAPSE*, the Picture Archiving Communication Systems (PACS), were strong.
- In the endoscope field, strong sales of *LASEREO*, an endoscope system equipped with a laser light source, were seen in domestic and overseas markets.
- In the ultrasound diagnostics field, sales of products which meet needs for operability and robustness in clinical fields increased particularly in Japan, the U.S., Europe, Asia and the Middle East region.
- In the IVD field, sales significantly increased due to the addition of clinical diagnostic reagents business in Wako Pure Chemical Industries, Ltd. (*FUJIFILM Wako Pure Chemical Corporation*), which become a consolidated subsidiary in April 2017.

### Pharmaceuticals, Bio CDMO

#### Principal Products and Services

- ▶ Small-molecule drugs
- ▶ Contract development and manufacturing organization of biopharmaceuticals
- ▶ Radiopharmaceuticals



Culturing tank for biopharmaceutical manufacturing

#### Performance Highlights and Major Initiatives

- Overall sales decreased, mainly due to the influence of generic drugs in the market for small-molecule drugs.
- In the bio CDMO business, the sales in business for contract development and manufacturing biopharmaceuticals progressed steadily. Production sites in Texas, U.S. started operations in January 2018. Furthermore, Fujifilm decided to accelerate the schedule to bolster its capacity to produce biopharmaceuticals at its production sites in the U.S. and to expand its facility in the UK for the development of production processes.
- In May 2018, management decided to turn Toyama Chemical Co., Ltd. into a wholly owned subsidiary and merged it with *FUJIFILM RI Pharma Co., Ltd.* in October 2018 in order to accelerate the development of new diagnostic and therapeutic drugs.



## Regenerative Medicine

### Principal Products and Services

- ▶ iPS cells for drug discovery support
- ▶ Recombinant peptide
- ▶ Autologous cultured epidermis/cartilage



Autologous cultured epidermis JACE

### Performance Highlights and Major Initiatives

- Autologous cultured epidermis *JACE* contributed to sales revenue from an increase in sales orders, which was partly due to the receipt of a new indication from December 2016 onwards, for the treatment of giant congenital melanocyte nevus.
- In March 2018, the Company announced the acquisition of Irvine Scientific Sales Company, Inc. and IS JAPAN CO., LTD., leading companies in the culture media, and then turned them into consolidated subsidiaries in June. In addition to achieve further growth in the cell culture media business, maximum synergy will be generated through continued expansion of the CDMO business for pharmaceuticals, and acceleration of R&D in the area of regenerative medicine.

## Life Sciences

### Principal Products and Services

- ▶ Functional cosmetics
- ▶ Nutritional supplement products
- ▶ Hair care products



ASTALIFT BB CREAM



ASTALIFT WHITE BRIGHT LOTION

### Performance Highlights and Major Initiatives

- Sales revenue increased due to strong sales of skin whitening products such as *ASTALIFT WHITE BRIGHT LOTION*, as well as other products such as *MetabARRIER S*, which is certified as Foods with Function Claims.
- Robust sales were also recorded for *ASTALIFT BB CREAM*, which is a new lineup of base makeup products.

## Highly Functional Materials

Revenue JPY **267.4** billion

### Display Materials

#### Principal Products and Services

- ▶ Protective film for polarizers
- ▶ Film for expanding viewing angles
- ▶ Materials for OLED/touch panel

FUJITAC protective film for polarizers



### Performance Highlights and Major Initiatives

- Although sales of existing TAC film declined due to inventory adjustment, sales grew of products in new fields related to touch panel and OLED.

## Industrial Products, Electronic Materials, Fine Chemicals

### Principal Products and Services

#### Industrial Products

- ▶ Non-destructive testing equipment and materials
- ▶ Touch panel materials

#### Electronic Materials

- ▶ Semiconductor processing materials

#### Fine Chemicals

- ▶ Highly functional chemicals
- ▶ Laboratory chemicals

### Performance Highlights and Major Initiatives

#### Industrial Products

- Sales were favorable for the touch panel sensor film *EXCLEAR*, industrial-use X-ray film and the pressure-measurement film *Prescale*.
- Sales fell due to the transfer of the paper business and the printer system business.

#### Electronic Materials

- A substantial increase in sales was seen reflecting strong sales of such advanced products as photoresist and peripheral materials related to photolithography, CMP slurries, and Image Sensor Color Mosaic and others.

#### Fine Chemicals

- Sales increased for highly functional chemicals such as polymerization initiators which are a raw material for high water absorption resin, used in daily necessities such as paper diapers.
- Fujifilm combined Wako Pure Chemical Industries, Ltd. and FUJIFILM Finechemicals Co., Ltd. on April 1, 2018. The new company name is FUJIFILM Wako Pure Chemical Corporation.

## Recording Media

Revenue JPY **40.4** billion

### Principal Products and Services

- ▶ Magnetic recording tape for computers
- ▶ Data archive service



LTO Ultrium 7 data cartridge computer tape with BaFe magnetic particles

### Performance Highlights and Major Initiatives

- Revenues decreased due to the inventory adjustment of magnetic tape for data storage and other factors.
- Encouraging the spread of its data archive service, *dternity*, and others to certainly meet customers' needs in this big data era.

## Graphic Systems

Revenue JPY **250.9** billion

### Principal Products and Services

- ▶ Printing materials, CTP plates
- ▶ Digital printing equipment
- ▶ Inkjet digital presses
- ▶ Industrial inkjet printheads



Wide format UV inkjet printer *Acuity Select* series

### Performance Highlights and Major Initiatives

- Revenues declined from lower sales of graphic arts film and printing plates due to weaker total demand, but sales increased for fully processless thermal CTP plates that help reduce environmental impacts.
- Fujifilm announced the Green Graphic Project as a new initiative to reduce CO<sub>2</sub> emissions.
- FUJIFILM Corporation and Fuji Xerox reorganized their sales functions for inkjet digital presses, and established a sales framework with stronger solutions and marketing capabilities.
- Sales were favorable for ink and industrial inkjet printheads.

## Business topics

### Healthcare & Material

## Use of AI/IoT in Medical IT Field

PACS is a system for interpreting images. Diagnostic imaging taken with CT, MRI, DR and other medical diagnostic imaging systems are stored on servers and then shown to doctors on displays within the hospital.

As diagnostic imaging systems become more advanced, the number of images taken has increased sharply.

A solution is needed for doctors so they can efficiently interpret and diagnose these images.

Fujifilm is currently advancing R&D in AI technologies and solutions for improving image diagnosis, combining deep learning technology with its strengths in image processing and recognition technologies accumulated over many years in the photographic film field.

Fujifilm aims to contribute to the maintenance and improvement of everyone's health by increasing diagnostic efficiency and the quality of healthcare by developing and providing a wide range of products and services in line with the diverse needs of clinical settings, applying AI technologies to big data related to diagnostic information.



<Image of AI technologies being utilized>  
Automatically detects lesions on images (the red area) and reduces overlooked risks





# Document Solutions

## Office Products & Printers

Provides digital multifunction devices and printers for offices and consumables, in addition to document solutions using cloud and mobile technologies.


## Production Services

Provides high-speed, high-quality digital printing systems and associated services as well as solution-oriented document services, such as printing work flow solutions, in the commercial printing field.


## Solutions & Services

Supports the resolution of management issues through services that improve corporate document and operational processing, such as solution services and managed print services (MPS) using AI and IoT.


### Proportion of revenue



### Revenue



### Operating income/ Operating margin



\* Operating income for FY2018/3 came to JPY 84.0 billion, excluding one-time expenses related to structural reforms.

### Business opportunities

- Stronger demand for office equipment and related services in emerging markets such as China and Southeast Asia
- Expansion of markets for solutions and services utilizing AI and cloud computing in advanced countries like Japan, where needs are growing for higher office productivity amid a push to increase work efficiency and reform work styles
- Expansion of the industrial printing market for textiles and packaging, and growth in inkjet digital printing in these markets

### Risks

- Decline in the number of pages printed on office equipment due to advances in digital technologies
- Lower profitability due to tougher competition in office equipment markets in advanced countries

### Performance Summary of FY2018/3

Consolidated revenue declined 3.1% from the previous fiscal year to JPY 1,047.8 billion, owing to contraction in the low-margin, low-end printer business and weaker sales in the Oceania region.

Segment operating income fell 83.1% to JPY 14.0 billion, reflecting one-time costs of JPY 70 billion that included restructuring charges.

In the office products field of the office products & printer business, sales volume declined for multifunction devices in Japan and the Oceania region, but overall sales volume rose slightly from the previous fiscal year thanks to strong sales in China and brisk exports to Europe and the U.S. In the office printers field, sales volume fell alongside contraction in the low-margin, low-end printer business.

In the production services business, annual sales volume declined.

In the solutions & services business, sales were robust for business-specific solutions, but revenue decreased year on year due to a change in an accounting practice for purchased products.

## Office Products & Printers

Revenue JPY **610.0** billion

### Principal Products and Services

- ▶ Office-use color/monochrome digital multifunction devices
- ▶ Color/monochrome printers

Office-use full-color digital multifunction device  
*ApeosPort-VI C7771*



### Performance Highlights and Major Initiatives

- Sales volume declined for multifunction devices in Japan and the Oceania region.
- Overall sales volume of multifunction devices rose slightly from the previous fiscal year, thanks to brisk sales in China and higher exports of new products to Europe and the U.S.
- Sales volume of printers decreased from contraction in the low-margin, low-end printer business.

## Production Services

Revenue JPY **131.0** billion

### Principal Products and Services

- ▶ On-demand publishing systems
- ▶ Computer printing systems



*Iridesse™ Production Press*, a color on-demand publishing system for the printing market

### Performance Highlights and Major Initiatives

- Annual sales volume decreased.
- Sales were favorable for the *Iridesse™ Production Press*, a color on-demand publishing system launched in November 2017.
- Fuji Xerox refreshed its lineup of monochrome high-speed production printers in February 2018 to support various operations in the office and graphic arts markets and mission critical tasks.

## Solutions & Services

Revenue JPY **256.2** billion

### Principal Products and Services

- ▶ Business-specific solutions
- ▶ Managed print services (MPS)
- ▶ Business process outsourcing (BPO)

### Performance Highlights and Major Initiatives

- Sales remained strong for business-specific solutions such as management solutions for engineering drawings.
- Revenue was robust for existing business process outsourcing (BPO) contracts.
- Overall revenue fell year on year due to a change in an accounting practice for recognizing revenue from purchased products.

### Business topics

#### Document

## New Value Provision Strategy “Smart Work Innovation”

In March 2018, Fuji Xerox came up with a new value provision strategy called “Smart Work Innovation” as a solution service that supports work style reforms at its customers.

Fuji Xerox aims to assist its customers in realizing higher corporate competitiveness, improved productivity and creative work style reforms by leveraging its accumulated research in the Document AI, IoT, and IoH (Internet of Humans) fields, in addition to its strength in providing solutions and services tailored to customers’ industries and operations through multifunction devices.

In April 2018, Fuji Xerox announced several new solutions and services, including a high-precision data entry service, engineering drawing information extraction service, expert knowledge systemization service, cloud security service and behavioral analysis optimization service.

### Smart work innovation overall concept

#### Document AI\*

**Systemize and Utilize Information**  
Fuji Xerox helps workers demonstrate their creativity by converting distributed, hard-to-use information to valuable one.

#### Next-generation security

**Protect Information**  
Fuji Xerox provides cloud-based security infrastructure covering office equipment, mobile and IoT devices.

#### IoH Intelligent portal

**Collect and Utilize Information**  
As an evolved multifunction printer and various other forms, Intelligent Portal—which collects various data in offices and extracts valuable knowledge that was embedded in documents, people and other things—provides values to office work as a portal to leverage information from various sources.

\* Document AI is Fuji Xerox’s proprietary AI technology that extracts valuable intelligence from documents.